CPHS Seminar: Appraising rare disease treatments – How do we determine value? Title: Appraising rare disease treatments – How do we determine value? Summary: Health Technology Assessment/Appraisal (HTA) provides a scientific and policy framework to support accountable decisions about whether to invest in new interventions in the health service, for example as implemented by the Scottish Medicines Consortium (SMC). However, in Scotland, like other countries, there have been challenges about decisions relating to rare disease treatments, which have a small clinical evidence base, major uncertainties in economic modelling and high prices leading to value for money estimates that are much higher than traditional willingness to pay thresholds. There is concern that traditional economic models, particularly the use of the Quality Adjusted Life Year (QALY), do not capture all elements of value and that wider considerations and special processes are needed. This seminar will reflect on these issues and discuss work emerging from the EC H2020 IMPACT HTA Work Package led by Usher, including an international review of existing appraisal processes, ethnographic observation of processes at SMC and NICE and the potential for outcome based conditional approvals. Speaker: Dr. Karen Facey Bio: Karen Facey is a part-time Senior Research Fellow in the Usher Institute. After working as a senior statistician in the pharmaceutical sector and UK medicines regulation, she became the founding Chief Executive of the first national health technology assessment (HTA) agency in Scotland. For the past 15 years, Karen has been an independent consultant on health policy, HTA and patient involvement. She has served as a board member on two Scottish health boards, chaired Scottish Government committees revising the NHS Scotland funding formula and is a member of the Scottish Health Technologies Groups. She is a Trustee of Health Technology Assessment international and the Royal Statistical Society. In 2014 she was named as one of the top 100 practising scientists in the UK for her work in HTA and patient involvement. Lunch will be provided. Oct 02 2019 12.00 - 13.00 CPHS Seminar: Appraising rare disease treatments – How do we determine value? CPHS Seminar Craigmillar Room, BioQuarter, NINE Register with Eventbrite
CPHS Seminar: Appraising rare disease treatments – How do we determine value? Title: Appraising rare disease treatments – How do we determine value? Summary: Health Technology Assessment/Appraisal (HTA) provides a scientific and policy framework to support accountable decisions about whether to invest in new interventions in the health service, for example as implemented by the Scottish Medicines Consortium (SMC). However, in Scotland, like other countries, there have been challenges about decisions relating to rare disease treatments, which have a small clinical evidence base, major uncertainties in economic modelling and high prices leading to value for money estimates that are much higher than traditional willingness to pay thresholds. There is concern that traditional economic models, particularly the use of the Quality Adjusted Life Year (QALY), do not capture all elements of value and that wider considerations and special processes are needed. This seminar will reflect on these issues and discuss work emerging from the EC H2020 IMPACT HTA Work Package led by Usher, including an international review of existing appraisal processes, ethnographic observation of processes at SMC and NICE and the potential for outcome based conditional approvals. Speaker: Dr. Karen Facey Bio: Karen Facey is a part-time Senior Research Fellow in the Usher Institute. After working as a senior statistician in the pharmaceutical sector and UK medicines regulation, she became the founding Chief Executive of the first national health technology assessment (HTA) agency in Scotland. For the past 15 years, Karen has been an independent consultant on health policy, HTA and patient involvement. She has served as a board member on two Scottish health boards, chaired Scottish Government committees revising the NHS Scotland funding formula and is a member of the Scottish Health Technologies Groups. She is a Trustee of Health Technology Assessment international and the Royal Statistical Society. In 2014 she was named as one of the top 100 practising scientists in the UK for her work in HTA and patient involvement. Lunch will be provided. Oct 02 2019 12.00 - 13.00 CPHS Seminar: Appraising rare disease treatments – How do we determine value? CPHS Seminar Craigmillar Room, BioQuarter, NINE Register with Eventbrite
Oct 02 2019 12.00 - 13.00 CPHS Seminar: Appraising rare disease treatments – How do we determine value? CPHS Seminar
